Literature DB >> 10764312

Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.

D E Niewoehner1, D Collins, M L Erbland.   

Abstract

FEV(1) is an objective measure of airflow obstruction used in clinical practice and in therapeutic trials. The precise relationship of FEV(1) to clinical outcomes is generally uncertain. As part of a randomized trial to assess systemic corticosteroid efficacy, we obtained serial FEV(1) measurements in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD). Over the first 14 Study Days at least one FEV(1) value was obtained in 261 subjects. Sixty-four of these subjects experienced treatment failure, defined as death, intubation, readmission for COPD, or intensification of drug therapy, by Study Day 30. After adjustment, both FEV(1) at entry into the study (odds ratio [OR] for a 100-ml increase, 0.87; 95% confidence interval [CI], 0.79 to 0.96) and change in FEV(1) over the first two Study Days (OR for a 100 ml increase, 0.80; 95% CI, 0.69 to 0.92) predicted treatment failure. We identified no baseline characteristic that was significantly related to FEV(1) at entry into the study. Assignment to the systemic corticosteroid treatment arm was associated with a significantly larger FEV(1) at Study Day two (p = 0.01). We conclude that FEV(1) measurements at admission and over the first several days of hospitalization are highly predictive of clinical outcomes during exacerbations of COPD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764312     DOI: 10.1164/ajrccm.161.4.9907143

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  20 in total

1.  [Austrian Society for Pulmonary Diseases and Tuberculosis. Consensus concerning the management of chronic obstructive pulmonary diseases (COPD). Revised draft 2004].

Authors:  Lutz H Block; Otto C Burghuber; Sylvia Hartl; Hartmut Zwick
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

2.  Intermediate care--Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline.

Authors: 
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

3.  Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry.

Authors:  Martin K Johnson; Malcolm Birch; Roger Carter; John Kinsella; Robin D Stevenson
Journal:  Thorax       Date:  2006-11-14       Impact factor: 9.139

Review 4.  Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

Authors:  Matthew C Miles; James F Donohue; Jill A Ohar
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

5.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

Review 6.  Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.

Authors:  B Jarvis; A Markham
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  COPD exacerbations . 3: Pathophysiology.

Authors:  D E O'Donnell; C M Parker
Journal:  Thorax       Date:  2006-04       Impact factor: 9.139

8.  Three-month treatment response and exacerbation in chronic obstructive pulmonary disease.

Authors:  Jung Su Lee; Chin Kook Rhee; Kwang Ha Yoo; Ji-Hyun Lee; Ho Il Yoon; Tae-Hyung Kim; Woo Jin Kim; JinHwa Lee; Seong Yong Lim; Tai Sun Park; Jae Seung Lee; Sei Won Lee; Sang-Do Lee; Yeon-Mok Oh
Journal:  J Korean Med Sci       Date:  2014-12-23       Impact factor: 2.153

Review 9.  Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence.

Authors:  Ken M Kunisaki; Kathryn L Rice; Dennis E Niewoehner
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 10.  Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature.

Authors:  Helen Doll; Marc Miravitlles
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.